Receive Clinical Grade Stem Cells

Based on 20 Years
of Leading Research

Cellcolabs Clinical is conducting clinical trials in the Bahamas using Mesenchymal Stem Cells (MSCs). Our MSCs are produced in Sweden and based on a manufacturing protocol developed at the world-renowned Karolinska Institute. 

Book free consultation
Upcoming Webinars

Clinical trials

  • Prevention of Cardiovascular Disease
  • Musculoskeletal Injuries
  • Aging Frailty
  • Osteoarthritis

Bone marrow-derived mesenchymal stem cells

  • High-quality stem cells sourced from bone marrow of healthy, voluntary donors.
  • Produced in Cellcolabs’ production facility in Sweden.

Safety profile

  • Analysis of 15+ years of MSC research indicates a strong safety profile.
  • Cell production according to GMP (Good Manufacturing Practice).

Widely researched

  • Based on over 20 years of academic research at Karolinska Institute.
  • Over hundreds of clinical trials globally on MSCs.

Our Trials

We are currently conducting several clinical trials with MSCs. These include Prevention of cardiovascular disease, Musculoskeletal injuries and/or degeneration; and Ageing frailty.

Eligibility for the trials will be determined by the relevant Principal Investigator. More information on inclusion and exclusion criteria is available during the sign-up process.

Prevention of Cardiovascular Disease

This clinical trial investigates the potential of MSCs in prevention of cardiovascular disease and follows several longevity and disease biomarkers.

Cardiovascular disease is the leading cause of death globally, taking an estimated 20 million lives each year. Prevention is a proactive approach to healthcare that seeks to maintain health and prevent development of illness.

You may be eligible if you:

  • Are aged 25-85
  • Have no known malignant disease
  • Do not fulfil any of our exclusion criteria
Read More

Musculoskeletal Injuries

Musculoskeletal injuries and degeneration may occur for various reasons, such as accidents, sports injuries, genetics, or just wear and tear.

Depending on your condition you may be eligible for local and/or systemic treatment.

You may be eligible if you are 18 years or older and have:

  • A diagnosed acute or chronic musculoskeletal condition
  • A recent injury that has been adequately treated
  • Recurring symptoms of a previous injury
Read More

Ageing Frailty

The geriatric syndrome of frailty is a common clinical syndrome based on the accumulation of multi-systemic function declines and the increase in susceptibility to stressors during biological ageing.

This can manifest in a variety of symptoms, such as decreased muscle strength, reduced mobility, and impaired cognitive function.

Frailty can also increase an elderly persons risk of falls, hospitalization, and other negative health outcomes.

You may be eligible if you:

  • Are between 60-85 years old
  • Are mildly or moderately frail
  • Have a 6-minute walk distance of more than 200m and less than 400m
Read More

Osteoarthritis

Osteoarthritis is the most common form of arthritis and is also known as degenerative arthritis and OA. It occurs most frequently in the hands, hips, and knees.

A common symptom of OA is a stiff and painful feeling around the joints.

Please note that this is not a separate trial. Treatments for OA will be included in the musculoskeletal injuries and degeneration trial.

Read More

About

Continuing the Research from
the Karolinska Institute

Mesenchymal stem cells (MSCs) are a type of multipotent stem cell with anti-inflammatory, immunomodulatory and regenerative characteristics. They have been intensively researched over the past decades, and currently, there are hundreds of clinical trials with MSCs for a broad spectrum of conditions (1).

The MSCs used in these trials are produced by Cellcolabs AB at their facility in Stockholm, Sweden. The production process has been optimised through 25 years of academic research, and the cells are quality controlled according to the guidelines of the International Society for Cell and Gene Therapy (2). The manufacturing is approved by the Swedish Medical Products Agency and certified under GMP (Good Manufacturing Practice) standards. The clinical trials have received approval by local authorities.

Cellcolabs’ MSCs are derived from the bone marrow of healthy donors aged 18-30. These cells are likely more potent than cells derived from trial participants themselves (3-4). Using donated cells also means that trial participants do not need to endure cell extraction as part of the trial.

Mesenchymal stem cells (MSCs) are a type of multipotent stem cell with anti-inflammatory, immunomodulatory and regenerative characteristics. They have been intensively researched over the past decades, and currently, there are hundreds of clinical trials with MSCs for a broad spectrum of conditions (1).

The MSCs used in these trials are produced by Cellcolabs AB at their facility in Stockholm, Sweden. The production process has been optimised through 25 years of academic research, and the cells are quality controlled according to the guidelines of the International Society for Cell and Gene Therapy (2). The manufacturing is approved by the Swedish Medical Products Agency and certified under GMP (Good Manufacturing Practice) standards. The clinical trials have received approval by local authorities.

Cellcolabs’ MSCs are derived from the bone marrow of healthy donors aged 18-30. These cells are likely more potent than cells derived from trial participants themselves (3-4). Using donated cells also means that trial participants do not need to endure cell extraction as part of the trial.

More About Our Stem Cells
More about Cellcolabs Clinical

Timeline

A Simple Process to Participate

01 - Sign Up

Sign up through this website if you want to receive more information and inquire if a clinical trial would suit you.

Note that sign-up is not binding and incurs no cost.

02 – Consultation

After sign-up, you will be contacted for a phone or video consultation with one of our Clinical Advisors.

You will receive further information and your preferences and needs are noted to prepare your personalized offer. If relevant, a consultation with a clinician is made available.

03 – Confirmation

Depending on eligibility, you will receive an offer to participate along with formal practicalities.

Following your acceptance, you will be booked for a date, and the participation fee will be invoiced.

04 – Treatment

You will meet with the study doctor at the trial clinic, who will take your medical history and examine you.

Depending on the study, baseline blood tests may be taken. You will be asked to sign an informed consent form and answer multiple questionnaires relating to your health. The entire process will take approximately 4 hours.

05 – Follow-Up

You will have scheduled follow-ups that include questionnaires, blood tests, and physical exams. Remote options are available for those unable to return to the Bahamas.

The program is designed to closely monitor your progress and provide a comprehensive analysis of treatment outcomes.

Eligibility To Participate in the Clinical Trials

Check if you're eligible

Clinics

Treatment Location

Our clinical trials are conducted in the Bahamas, a country known for its high-quality healthcare and ambitious research in regenerative medicine.

The Bahamas

The Bahamas is a destination for both tourism and medicine, and the country is at the forefront of clinical stem cell applications. They allow patient-funded clinical trials, which is an opportunity to accelerate the research.

Our local partnering physicians have long experience of stem cell therapies. The clinical trials are approved by the Bahamas National Stem Cell Ethics Committee.

1. Search for: mesenchymal | Card Results | ClinicalTrials.gov 

2. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905  

3. Schultz, M.B. and Sinclair, D.A., 2016. When stem cells grow old: phenotypes and mechanisms of stem cell aging. Development, 143(1), pp.3-14.

4. Karin Stenderup, Jeannette Justesen, Christian Clausen, Moustapha Kassem, Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells, Bone, Volume 33, Issue 6, 2003, Pages 919-926, ISSN 8756-3282, https://doi.org/10.1016/j.bone.2003.07.005.